74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Sartorius Stedim Biotech.
Closed
SectorFinance
151.5 -3.69
Overview
Share price change
24h
Min
150.6
Max
157.3
Income | 41M 88M |
|---|---|
Sales | -11M 762M |
P/E Sector Avg | 58.498 37.736 |
EPS | 1.17 |
Profit margin | 11.569 |
Employees | 10,456 |
EBITDA | 26M 225M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +45.9% upside |
Next Earnings | 23 Jul 2026 |
|---|
Market Cap | -2.6B 16B |
|---|---|
Previous open | 155.19 |
Previous close | 151.5 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Sartorius Stedim Biotech. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sartorius Stedim Biotech. Forecast
Price Target
By TipRanks
45.9% upside
12 Months Forecast
Average 233 EUR 45.9%
High 262 EUR
Low 210 EUR
Based on 8 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sartorius Stedim Biotech.
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Live chat